At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
ESK981drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
In Brief
A Phase 2 clinical trial evaluating ESK981 for Castration Levels of Testosterone and 4 related conditions. Completed, enrolled 13 participants across 2 sites.
Detailed Summary
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. ESK981 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCastration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMar 2018
Primary CompletionMar 2023
Study CompletionMay 2023
TodayJul 2026
First PostedMar 7, 2018
Enrollment StartMar 8, 2018
Primary CompletionMar 15, 2023
Study CompletionMay 9, 2023
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.3 years ago
Interventions
ESK981drug
Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer